ArticlePloS one2025
The SII-PNI score: A novel composite biomarker for personalized mortality risk prediction in peritoneal dialysis patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between prognostic nutritional index and mortality in patients with sepsis-associated delirium: a retrospective cohort study using the MIMIC-IV database.BMC nutrition · 2026Article
- Article
- New insights into the association between cardiometabolic index with metabolic profile, nutritional status, and inflammaging in older adults.Frontiers in aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccurate risk stratification is crucial for personalized management in peritoneal dialysis (PD). This study aimed to develop and validate a novel biomarker, the SII-PNI score, integrating systemic immunoinflammatory index (SII) and prognostic nutritional index (PNI), for personalized mortality risk prediction in PD patients.
methodsA retrospective cohort study analyzed data from 330 patients initiating PD between December 2005 and June 2023 at a single center. Patients were stratified into four risk groups based on median cut-off values for SII and PNI. The association between SII-PNI risk groups and mortality (all-cause, cardiovascular [CVD], infection-related) was assessed using Kaplan-Meier survival analysis and multivariable Cox proportional hazard models. The predictive performance of the SII-PNI score was evaluated using receiver-operating characteristic (ROC) curves and compared to individual components (SII, PNI) and CRP. Random survival forests assessed variable importance.
resultsThe high-risk group (G4: high SII + low PNI) had the shortest PD duration, highest mortality, and worst survival outcomes. Compared to the low-risk group (G3: low SII + high PNI), G4 had significantly increased risks of all-cause mortality (adjusted HR 3.36, 95% CI 1.93-8.67), CVD mortality (adjusted HR 3.74, 95% CI 2.41-19.60), and infection mortality (adjusted HR 4.32, 95% CI 2.58-20.4) in fully adjusted models. The SII-PNI score demonstrated superior predictive ability (AUC: all-cause 0.80, CVD 0.80, infection 0.81) compared to SII, PNI, or CRP alone. Random survival forests confirmed the critical importance of the individual components (platelets, neutrophils, lymphocytes, albumin) for outcomes.
conclusionsThe SII-PNI score, derived from readily available blood parameters, is a powerful and convenient tool for personalized risk stratification in PD. Patients identified as high-risk warrant intensified monitoring and early interventions. This composite biomarker represents a significant step towards personalized and precision medicine in PD care, with potential for implementation in routine clinical practice using standard laboratory data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.